Buy & Sell Datadog Inc (DDOG) – Datadog Inc Price Today
Aura AI Summary
Key Stats
- $85.35BMarket Cap
- TechnologySector
- -20.51%3M Drawdown
- $81.88BEnterprise Value
- -Dividend Yield
- 75 daysTypical Hold Time
Datadog Inc (DDOG) is currently valued at a market capitalization of $85.35B, with an enterprise value of $81.88B. Over the past 52 weeks, Datadog Inc has traded between a low of $102.62 and a high of $277.49, highlighting its annual price range. Over the past three months, Datadog Inc has recorded a drawdown of -20.51%, reflecting recent price volatility. On average, investors hold Datadog Inc for approximately 75 days, indicating typical investor behavior on the platform.
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Most Recent News
State Street Global Advisors reduces stake in DCC plc below 1.4% with recent share sales.
State Street Global Advisors & Affiliates disclosed a reduction in their holdings of DCC plc ordinary shares to 1,193,218 shares, representing 1.39682% of the company. The reduction involved selling 1,544 shares at €62.30 each on June 26, 2026. This ...

Global head-up display market to nearly double to $13.7B by 2030, driven by digital cockpits and EV growth.
The global head-up display (HUD) market is expected to grow from $6.9 billion in 2024 to $13.7 billion by 2030, at a CAGR of 12.8%, fueled by rising demand for digital cockpits and advanced driver assistance systems in vehicles. Asia-Pacific leads wi...

Study shows 1 in 7 patients switch back to Humira after moving to biosimilars post-formulary changes
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
